![David Clark Bennett](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di David Clark Bennett
Precedenti posizioni note di David Clark Bennett
Società | Posizione | Inizio | Fine |
---|---|---|---|
OtoMedicine, Inc.
![]() OtoMedicine, Inc. Pharmaceuticals: OtherHealth Technology OtoMedicine, Inc. is a new biopharmaceutical company, founded in 2006, to commercialize more than two decades of scientific research and technology developed in the laboratories of Dr. Josef Miller at the University of Michigan's Kresge Hearing Research Institute. OtoMedicine's mission is to become the leading provider of medicines to prevent, treat, and cure hearing loss. Its initial focus is to amplify, in a compelling manner, the evidence it has already gathered to demonstrate that a proprietary combination of compounds can dramatically reduce noise-induced hearing loss (NIHL), one of the most prevalent disabling conditions in the industrialized world and for which there is no FDA-approved means of treatment. Called AuraquellTM, this specific combination of micronutrients has already been shown to provide significant synergistic protection against noise-induced injury in pre-clinical studies with animal subjects. In other words, the protection resulting from administration of the combination was greater than that following any of the ingredients individually. Based on the dramatic protection observed in pre-clinical studies, this formulation is expected to be a highly effective therapy for prevention of NIHL in humans. | Direttore Tecnico/Scientifico/R&S | 01/01/2004 | 07/02/2013 |
Fondatore | 01/01/2004 | 07/02/2013 | |
Treasurer | 01/01/2004 | 07/02/2013 |
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Treasurer | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
OtoMedicine, Inc.
![]() OtoMedicine, Inc. Pharmaceuticals: OtherHealth Technology OtoMedicine, Inc. is a new biopharmaceutical company, founded in 2006, to commercialize more than two decades of scientific research and technology developed in the laboratories of Dr. Josef Miller at the University of Michigan's Kresge Hearing Research Institute. OtoMedicine's mission is to become the leading provider of medicines to prevent, treat, and cure hearing loss. Its initial focus is to amplify, in a compelling manner, the evidence it has already gathered to demonstrate that a proprietary combination of compounds can dramatically reduce noise-induced hearing loss (NIHL), one of the most prevalent disabling conditions in the industrialized world and for which there is no FDA-approved means of treatment. Called AuraquellTM, this specific combination of micronutrients has already been shown to provide significant synergistic protection against noise-induced injury in pre-clinical studies with animal subjects. In other words, the protection resulting from administration of the combination was greater than that following any of the ingredients individually. Based on the dramatic protection observed in pre-clinical studies, this formulation is expected to be a highly effective therapy for prevention of NIHL in humans. | Health Technology |
- Borsa valori
- Insiders
- David Clark Bennett
- Esperienza